Skip to main content

KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Genentech requests that their press release NewsItemId: 20240125093104 “New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)” be killed.

The release was issued prematurely by Genentech.

A replacement release will be issued at a later date.

Contacts

Media Contact:

Shirley Dang, (650) 467-6800

Advocacy Contact:

Danielle Haney, (240) 805-4810

Investor Contacts:

Loren Kalm, (650) 225-3217

Bruno Eschli, +41 61 687 5284

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.67
+0.29 (0.12%)
AAPL  341.07
+5.15 (1.53%)
AMD  630.63
+1.37 (0.22%)
BAC  56.70
+0.67 (1.20%)
GOOG  341.08
+2.07 (0.61%)
META  751.66
-25.93 (-3.33%)
MSFT  516.17
+18.24 (3.66%)
NVDA  225.07
+0.49 (0.22%)
ORCL  137.10
-2.44 (-1.75%)
TSLA  372.11
-5.83 (-1.54%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.